Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
PurposeEndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free i...
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2019 |
| Country: | España |
| Institution: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repository: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p6995 |
| Online Access: | https://fisabio.portalinvestigacion.com/publicaciones/6995 |
| Access Level: | Open access |
| Keyword: | Chemotherapy Prediction Breast cancer EndoPredict |
| _version_ | 1878738383459581952 |
|---|---|
| author | Sestak, I |
| author2 | Martin, M Dubsky, P Kronenwett, R Rojo, F Cuzick, J Filipits, M Ruiz, A Gradishar, W Soliman, H Schwartzberg, L Buus, R Hlauschek, D Rodriguez-Lescure, A Gnant, M |
| author2_role | author author author author author author author author author author author author author author |
| author_browse | Buus, R Cuzick, J Dubsky, P Filipits, M Gnant, M Gradishar, W Hlauschek, D Kronenwett, R Martin, M Rodriguez-Lescure, A Rojo, F Ruiz, A Schwartzberg, L Sestak, I Soliman, H |
| author_facet | Sestak, I Martin, M Dubsky, P Kronenwett, R Rojo, F Cuzick, J Filipits, M Ruiz, A Gradishar, W Soliman, H Schwartzberg, L Buus, R Hlauschek, D Rodriguez-Lescure, A Gnant, M |
| author_role | author |
| collection | r-FISABIO. Repositorio Institucional de Producción Científica |
| description | PurposeEndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET+C).MethodsA total of 3746 women were included in this joint analysis. 2630 patients received 5years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET+C (GEICAM 2003-02/9906). The primary objective was to evaluate the ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone and ET+C. Cox proportional hazard models were used for these analyses.ResultsEPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49-3.13), P<0.0001) as well as in those who received ET+C (HR 2.27 (1.99-2.59), P<0.0001). Women who received ET+C had significantly smaller increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin=5; 12% ET+C vs. 20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-(interaction)=0.022).ConclusionsIn this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET+C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_ae1bd2e6fccbd2323d20ab8a2d2c7545 |
| institution | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| instname_str | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:fisabio.fundanetsuite.com:p6995 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | SPRINGER |
| publisherStr | SPRINGER |
| reponame_str | r-FISABIO. Repositorio Institucional de Producción Científica |
| spelling | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone Sestak, I Martin, M Dubsky, P Kronenwett, R Rojo, F Cuzick, J Filipits, M Ruiz, A Gradishar, W Soliman, H Schwartzberg, L Buus, R Hlauschek, D Rodriguez-Lescure, A Gnant, M Chemotherapy Prediction Breast cancer EndoPredict PurposeEndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the performance of EPclin for estimating 10-year distant recurrence-free interval (DRFI) rates for those who received adjuvant endocrine therapy (ET) alone compared to those with chemotherapy plus endocrine therapy (ET+C).MethodsA total of 3746 women were included in this joint analysis. 2630 patients received 5years of ET alone (ABCSG-6/8, TransATAC) and 1116 patients received ET+C (GEICAM 2003-02/9906). The primary objective was to evaluate the ability of EPclin to provide an estimate of the 10-year DR rate as a continuous function of EPclin separately for ET alone and ET+C. Cox proportional hazard models were used for these analyses.ResultsEPclin was highly prognostic for DR in women who received ET alone (HR 2.79 (2.49-3.13), P<0.0001) as well as in those who received ET+C (HR 2.27 (1.99-2.59), P<0.0001). Women who received ET+C had significantly smaller increases in 10-year DR rates with the increasing EPclin score than those receiving ET alone (EPclin=5; 12% ET+C vs. 20% ET alone). We observed a significant positive interaction between EPclin and treatment groups (P-(interaction)=0.022).ConclusionsIn this comparative non-randomised analysis, the rate of increase in DR with EPclin score was significantly reduced in women who received ET+C versus ET alone. Our indirect comparisons suggest that a high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease. SPRINGER https://fisabio.portalinvestigacion.com/publicaciones/6995 |
| spellingShingle | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone Sestak, I Chemotherapy Prediction Breast cancer EndoPredict |
| status_str | publishedVersion |
| title | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone |
| title_full | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone |
| title_fullStr | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone |
| title_full_unstemmed | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone |
| title_short | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone |
| title_sort | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone |
| topic | Chemotherapy Prediction Breast cancer EndoPredict |
| topic_facet | Chemotherapy Prediction Breast cancer EndoPredict |
| url | https://fisabio.portalinvestigacion.com/publicaciones/6995 |